Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma

Phase I testing of the hu14.18-IL2 immunocytokine (IC) in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m(2)/day. Preclinical data in IC-treated tumor-bearing mice with low tumor burden documented striking antitumor effects. Patients with c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Immunother
Main Authors: Albertini, Mark R., Yang, Richard K., Ranheim, Erik A., Hank, Jacquelyn A., Zuleger, Cindy L., Weber, Sharon, Neuman, Heather, Hartig, Greg, Weigel, Tracey, Mahvi, David, Henry, Mary Beth, Quale, Renae, McFarland, Thomas, Gan, Jacek, Carmichael, Lakeesha, Kim, KyungMann, Loibner, Hans, Gillies, Stephen D., Sondel, Paul M.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2018
Assuntos:
Clinical Trial Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6168354/
https://ncbi.nlm.nih.gov/pubmed/30073390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-018-2223-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados